Hematopoietic Stem Cell Transplantation and Cardiotoxicity

  • Annalisa Natale
  • Stella Santarone
  • Paolo Di Bartolomeo
Chapter

Abstract

Hematopoietic stem cell transplantation (HCT) is now used worldwide in the treatment of many malignant and non-malignant hematologic disorders and in the treatment of various solid tumors. Every year, many thousands of patients receive an autologous or allogeneic transplant procedure. Cardiac complications associated with HCT have been documented in several series, but the incidence of reported cardiotoxicity has varied largely among investigators, ranging from 2% to 28% probably reflecting patient selection, differences in HCT conditioning regimens and lack of universal grading system for cardiotoxic events.This chapter will focus on the cardiac complications occurring either in the early period following HCT or in the long-term phase.

References

  1. 1.
    Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17):1813–26.CrossRefPubMedGoogle Scholar
  2. 2.
    Lake RA, Robinson BW. Immunotherapy and chemotherapy—a practical partnership. Nat Rev Cancer. 2005;5(5):397–05.CrossRefPubMedGoogle Scholar
  3. 3.
    Markey KA, MacDonald KP, Hill GR. The biology of graft-versus-host disease: experimental systems instructing clinical practice. Blood. 2014;124(3):354–62.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Bensinger W. High-dose preparatory regimens. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG, editors. Thomas hematopoietic cell transplantation. 4th ed. West Sussex: Wiley-Blackwell Ed; 2004. p. 316–32.Google Scholar
  5. 5.
    Cazin B, Gorin NC, Laporte JP, et al. Cardiac complications after bone marrow transplantation: a report on a series of 63 consecutive transplantations. Cancer. 1986;57(10):2061–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Murdych T, Weisdorf DJ. Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977–1997. Bone Marrow Transplant. 2001;28(3):283–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Hertenstein B, Stefanic M, Schmeiser T, et al. Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant. J Clin Oncol. 1994;12(5):998–1004.CrossRefPubMedGoogle Scholar
  8. 8.
    Baello EB, Ensberg ME, Ferguson DW, et al. Effect of high dose cyclophosphamide and total-body irradiation of left ventricular function in adult patients with leukemia undergoing allogeneic bone marrow transplantation. Cancer Treat Rep. 1986;70(10):1187–93.PubMedGoogle Scholar
  9. 9.
    Jain B, Floreani AA, Anderson JR, et al. Cardiopulmonary function and autologous bone marrow transplantation: results and predictive value for respiratory failure and mortality. Bone Marrow Transplant. 1996;17(14):561–8.PubMedGoogle Scholar
  10. 10.
    Braverman AC, Antin JH, Plappert MT, et al. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol. 1991;9(7):1215–23.CrossRefPubMedGoogle Scholar
  11. 11.
    Bearman SI, Petersen FB, Schor RA, et al. Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk of cardiac toxicity. Bone Marrow Transplant. 1990;5(3):173–7.PubMedGoogle Scholar
  12. 12.
    Roziakova L, Bojtarova E, Mistrik M, et al. Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation. J Exp Clin Cancer Res. 2012;31:13.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Roziakova L, Mistrik M, Batorova A, et al. Can we predict clinical cardiotoxicity with cardiac biomarkers in patients after haematopoietic stem cell transplantation? Cardiovasc Toxicol. 2015;15(3):210–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Heitner S, Chou S. Cardiovascular complications. In: Maziarz R, Slater S, editors. Blood and marrow transplant handbook Comprehensive guide for patient care. 2nd ed. Heidelberg: Springer; 2015. p. 287–97.Google Scholar
  15. 15.
    Morandi P, Ruffini PA, Benvenuto GM, et al. Cardiac toxicity of high-dose chemotherapy. Bone Marrow Transplant. 2005;35(4):323–34.CrossRefPubMedGoogle Scholar
  16. 16.
    Shaw PJ, Nath CE, Lazarus HM. Not too little, not too much—just right! (Better ways to give high dose melphalan). Bone Marrow Transplant. 2014;49(12):1457–65.CrossRefPubMedGoogle Scholar
  17. 17.
    Feliz V, Saiyad S, Ramarao SM, Khan H, et al. Melphalan-induced supraventricular tachycardia: incidence and risk factors. Clin Cardiol. 2011;34(6):356–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Kuruvilla J, Forrest DL, Lavoie JC, et al. Characteristics and outcome of patients developing endocarditis following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2004;34(11):969–73.CrossRefPubMedGoogle Scholar
  19. 19.
    Bhattacharya S, Paneesha S, Chaganti S, et al. Viral myocarditis in a patient following allogenic stem cell transplant: diagnostic dilemma and management considerations. J Clin Virol. 2009;45(3):262–4.CrossRefPubMedGoogle Scholar
  20. 20.
    El-Asmar J, Kharfan-Dabaja MA, Ayala E. Acute pericarditis and tamponade from Coxsackie B3 in an adult Hematopoietic-Cell-Allograft recipient: a rare but potentially serious complication. Hematol Oncol Stem Cell Ther. 2016;9(2):82–5. pii: S1658-3876(15)00056-4. doi: 10.1016/j.hemonc.2015.06.004.CrossRefPubMedGoogle Scholar
  21. 21.
    Morris C, de Wreede L, Scholten M, et al. Chronic Malignancies and Lymphoma Working Parties of EBMT. Should the standard dimethyl sulfoxide concentration be reduced? Results of European Group for Blood and Marrow Transplantation prospective non interventional study on usage and side effect of dimethyl sulfoxide. Transfusion. 2014;54(10):2514–22.CrossRefPubMedGoogle Scholar
  22. 22.
    Zenhäusern R, Tobler A, Leoncini L, et al. Fatal cardiac arrhythmia after infusion of dimethyl sulfoxide-cryopreserved hematopoietic stem cells in a patient with severe primary cardiac amyloidosis and end-stage renal failure. Ann Hematol. 2000;79(9):523–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Antin JH, Ferrara JL. Cytokine dysregulation and acute graft versus-host disease. Blood. 1992;80(12):2964–68.PubMedGoogle Scholar
  24. 24.
    Moir D, Turner J, Ma D, et al. Autopsy findings in bone marrow transplantation. Pathology. 1982;14(2):197–204.CrossRefPubMedGoogle Scholar
  25. 25.
    Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft versus-host disease: a long term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69(2):204–17.CrossRefPubMedGoogle Scholar
  26. 26.
    Roberts S, Leeborg N, Loriaux M, et al. Acute graft-versus-host disease of the heart. Pediatr Blood Cancer. 2006;47(5):624–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Rackley C, Schultz K, Goldman F, et al. Cardiac manifestations of graft-versus-host disease. Biol Blood Marrow Transplant. 2005;11(10):773–80.CrossRefPubMedGoogle Scholar
  28. 28.
    Norkin M, Ratanatharathorn V, Ayash L, et al. Large pericardial effusion as a complication in adults undergoing SCT. Bone Marrow Transplant. 2011;46(10):1353–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Gilman AL, Kooy NW, Atkins DL, et al. Complete heart block in association with graft-versus-host disease. Bone Marrow Transplant. 1998;21(1):85–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Sun CL, Francisco L, Kawashima T, et al. Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Blood. 2010;116(17):3129–39.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Bhatia S, Robison LL, Francisco L, et al. Late mortality in survivors of autologous hematopoietic cell transplantation. Blood. 2005;105(11):4215–22.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Tichelli A, Passweg J, Wojcik D, et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2008;93(8):1203–10.CrossRefPubMedGoogle Scholar
  33. 33.
    Armenian SH, Chow EJ. Cardiovascular disease in survivors of hematopoietic cell transplantation. Cancer. 2014;120(4):469–79.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • Annalisa Natale
    • 1
  • Stella Santarone
    • 1
  • Paolo Di Bartolomeo
    • 1
  1. 1.Dipartimento di Ematologia, Medicina Trasfusionale e Biotecnologie, Unità di Terapia Intensiva Ematologica per il Trapianto EmopoieticoOspedale CivilePescaraItaly

Personalised recommendations